Literature DB >> 33807880

Two Siblings Homozygous for F508del-CFTR Have Varied Disease Phenotypes and Protein Biomarkers.

Zhihong Zhang1, Jin Wang2, Yanhui H Zhang3, Tonia E Gardner1,4, Elizabeth A Fitzpatrick2, Weiqiang Zhang1,4,5,6.   

Abstract

Two siblings with CF are homozygous for F508del (referred to as Subject A and Subject B). Despite having the same CFTR genotype and similar environment, these two subjects exhibited different disease phenotypes. We analyzed their medical records and CF Foundation Registry data and measured inflammatory protein mediators in their sputum samples. Then, we examined the longitudinal relationships between inflammatory markers and disease severity for each subject and compared between them. Subject A presented a more severe disease than Subject B. During the study period, Subject A had two pulmonary exacerbations (PEs) whereas Subject B had one mild PE. The forced expiratory volume in 1 s (FEV1, % predicted) values for Subject A were between 34-45% whereas for Subject B varied between 48-90%. Inflammatory protein mediators associated with neutrophils, Th1, Th2, and Th17 responses were elevated in sputum of Subject A compared with Subject B, and also in samples collected prior to and during PEs for both subjects. Neutrophilic elastase (NE) seemed to be the most informative biomarkers. The infectious burden between these two subjects was different.

Entities:  

Keywords:  CFTR; F508del-CFTR; biomarkers; cystic fibrosis (CF); disease phenotypes; infection; inflammation

Mesh:

Substances:

Year:  2021        PMID: 33807880      PMCID: PMC7961721          DOI: 10.3390/ijms22052631

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  36 in total

Review 1.  Cystic fibrosis.

Authors:  Jane C Davies; Eric W F W Alton; Andrew Bush
Journal:  BMJ       Date:  2007-12-15

Review 2.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

Review 3.  CFTR biomarkers: time for promotion to surrogate end-point.

Authors:  K De Boeck; L Kent; J Davies; N Derichs; M Amaral; S M Rowe; P Middleton; H de Jonge; I Bronsveld; M Wilschanski; P Melotti; I Danner-Boucher; S Boerner; I Fajac; K Southern; R A de Nooijer; A Bot; Y de Rijke; E de Wachter; T Leal; F Vermeulen; M J Hug; G Rault; T Nguyen-Khoa; C Barreto; M Proesmans; I Sermet-Gaudelus
Journal:  Eur Respir J       Date:  2012-08-09       Impact factor: 16.671

Review 4.  Lung disease modifier genes in cystic fibrosis.

Authors:  Loic Guillot; Julie Beucher; Olivier Tabary; Philippe Le Rouzic; Annick Clement; Harriet Corvol
Journal:  Int J Biochem Cell Biol       Date:  2014-02-22       Impact factor: 5.085

Review 5.  Aspergillus infections in cystic fibrosis.

Authors:  Jill King; Shan F Brunel; Adilia Warris
Journal:  J Infect       Date:  2016-05-11       Impact factor: 6.072

6.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

Review 7.  Biomarkers in Paediatric Cystic Fibrosis Lung Disease.

Authors:  Kathryn A Ramsey; André Schultz; Stephen M Stick
Journal:  Paediatr Respir Rev       Date:  2015-05-12       Impact factor: 2.726

Review 8.  Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

Authors:  Xiaoqing Guan; Yuning Hou; Fei Sun; Zhe Yang; Chunying Li
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

9.  Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease.

Authors:  Leen J M Seys; Fien M Verhamme; Anja Schinwald; Hamida Hammad; Danen Mootoosamy Cunoosamy; Claudie Bantsimba-Malanda; Alan Sabirsh; Eileen McCall; Liz Flavell; Ronald Herbst; Sharen Provoost; Bart N Lambrecht; Guy F Joos; Guy G Brusselle; Ken R Bracke
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

10.  IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.

Authors:  George M Solomon; Carla Frederick; Shaoyan Zhang; Amit Gaggar; Tom Harris; Bradford A Woodworth; Chad Steele; Steven M Rowe
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.